CNTY-101

Century Therapeutics, Inc. · Phase 1 active Biologic

At a glance

Generic name	CNTY-101
Sponsor	Century Therapeutics, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (PHASE1)
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CNTY-101 CI brief — competitive landscape report
CNTY-101 updates RSS · CI watch RSS
Century Therapeutics, Inc. portfolio CI